Baxter International Inc. (NYSE:BAX) Shares Sold by First National Bank & Trust Co. of Newtown

First National Bank & Trust Co. of Newtown decreased its holdings in shares of Baxter International Inc. (NYSE:BAX) by 2.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,467 shares of the medical instruments supplier’s stock after selling 465 shares during the quarter. First National Bank & Trust Co. of Newtown’s holdings in Baxter International were worth $739,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Oregon Public Employees Retirement Fund raised its holdings in shares of Baxter International by 0.7% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 43,751 shares of the medical instruments supplier’s stock worth $1,463,000 after purchasing an additional 310 shares in the last quarter. Kingswood Wealth Advisors LLC boosted its stake in shares of Baxter International by 4.6% during the 2nd quarter. Kingswood Wealth Advisors LLC now owns 7,759 shares of the medical instruments supplier’s stock worth $260,000 after acquiring an additional 343 shares in the last quarter. Archer Investment Corp raised its position in shares of Baxter International by 20.8% during the second quarter. Archer Investment Corp now owns 2,235 shares of the medical instruments supplier’s stock worth $75,000 after purchasing an additional 385 shares during the period. M&R Capital Management Inc. lifted its holdings in shares of Baxter International by 9.5% during the third quarter. M&R Capital Management Inc. now owns 4,480 shares of the medical instruments supplier’s stock valued at $170,000 after purchasing an additional 390 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Baxter International by 6.5% during the third quarter. GAMMA Investing LLC now owns 7,517 shares of the medical instruments supplier’s stock valued at $285,000 after purchasing an additional 459 shares during the last quarter. Institutional investors own 90.19% of the company’s stock.

Baxter International Stock Down 0.2 %

Baxter International stock opened at $36.04 on Friday. The company has a market capitalization of $18.39 billion, a P/E ratio of 7.42, a P/E/G ratio of 1.21 and a beta of 0.60. Baxter International Inc. has a 1-year low of $32.48 and a 1-year high of $44.01. The firm’s fifty day simple moving average is $37.50 and its 200-day simple moving average is $36.16. The company has a current ratio of 1.40, a quick ratio of 0.91 and a debt-to-equity ratio of 1.35.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.75 billion. During the same quarter in the previous year, the firm earned $0.55 earnings per share. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. Sell-side analysts forecast that Baxter International Inc. will post 2.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BAX. StockNews.com upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a research report on Tuesday, October 22nd. The Goldman Sachs Group lifted their target price on Baxter International from $36.00 to $40.00 and gave the company a “neutral” rating in a research note on Thursday, August 8th. Wells Fargo & Company lowered their price objective on shares of Baxter International from $44.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 7th. Morgan Stanley downgraded shares of Baxter International from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $39.00 to $30.00 in a research report on Monday, July 15th. Finally, Citigroup boosted their price target on shares of Baxter International from $38.00 to $40.00 and gave the company a “neutral” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $41.20.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.